← All trials
NCT02913118
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2016
- Primary completion
- Jan 1, 2018
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 462
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Qingfeng Pharmaceutical GroupLead sponsor
- Peking UniversityOverall official - principal investigator
- Qingdao Municipal HospitalOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- First Hospital of QinHuangDaoOverall official - principal investigator
- The Central Hospital of ZiBo CityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Nanchang UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.